ID   ABCD1_HUMAN             Reviewed;         745 AA.
AC   P33897; Q6GTZ2;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 2.
DT   27-MAR-2024, entry version 245.
DE   RecName: Full=ATP-binding cassette sub-family D member 1 {ECO:0000312|HGNC:HGNC:61};
DE            EC=3.1.2.- {ECO:0000269|PubMed:29397936, ECO:0000269|PubMed:33500543};
DE            EC=7.6.2.- {ECO:0000269|PubMed:11248239, ECO:0000269|PubMed:29397936, ECO:0000269|PubMed:33500543, ECO:0000305|PubMed:16946495, ECO:0000305|PubMed:23671276};
DE   AltName: Full=Adrenoleukodystrophy protein {ECO:0000303|PubMed:10777694};
DE            Short=ALDP {ECO:0000303|PubMed:16946495, ECO:0000303|PubMed:18757502};
GN   Name=ABCD1 {ECO:0000312|HGNC:HGNC:61}; Synonyms=ALD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=8441467; DOI=10.1038/361726a0;
RA   Mosser J., Douar A.-M., Sarde C.-O., Kioschis P., Feil R., Moser H.,
RA   Poustka A.-M., Mandel J.-L., Aubourg P.;
RT   "Putative X-linked adrenoleukodystrophy gene shares unexpected homology
RT   with ABC transporters.";
RL   Nature 361:726-730(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   SUBUNIT, AND CHARACTERIZATION OF VARIANTS ALD HIS-389; GLN-401; ARG-484 AND
RP   GLN-591.
RX   PubMed=10551832; DOI=10.1074/jbc.274.46.32738;
RA   Liu L.X., Janvier K., Berteaux-Lecellier V., Cartier N., Benarous R.,
RA   Aubourg P.;
RT   "Homo- and heterodimerization of peroxisomal ATP-binding cassette half-
RT   transporters.";
RL   J. Biol. Chem. 274:32738-32743(1999).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS ALD SER-512
RP   AND LEU-606.
RX   PubMed=11248239; DOI=10.1016/s0014-5793(01)02235-9;
RA   Roerig P., Mayerhofer P., Holzinger A., Gaertner J.;
RT   "Characterization and functional analysis of the nucleotide binding fold in
RT   human peroxisomal ATP binding cassette transporters.";
RL   FEBS Lett. 492:66-72(2001).
RN   [6]
RP   INTERACTION WITH PEX19, SUBCELLULAR LOCATION, AND REGION.
RC   TISSUE=Brain;
RX   PubMed=10777694; DOI=10.1006/bbrc.2000.2572;
RA   Gloeckner C.J., Mayerhofer P.U., Landgraf P., Muntau A.C., Holzinger A.,
RA   Gerber J.-K., Kammerer S., Adamski J., Roscher A.A.;
RT   "Human adrenoleukodystrophy protein and related peroxisomal ABC
RT   transporters interact with the peroxisomal assembly protein PEX19p.";
RL   Biochem. Biophys. Res. Commun. 271:144-150(2000).
RN   [7]
RP   INTERACTION WITH PEX19.
RX   PubMed=10704444; DOI=10.1083/jcb.148.5.931;
RA   Sacksteder K.A., Jones J.M., South S.T., Li X., Liu Y., Gould S.J.;
RT   "PEX19 binds multiple peroxisomal membrane proteins, is predominantly
RT   cytoplasmic, and is required for peroxisome membrane synthesis.";
RL   J. Cell Biol. 148:931-944(2000).
RN   [8]
RP   INDUCTION.
RX   PubMed=16213491; DOI=10.1016/j.febslet.2005.09.014;
RA   Weinhofer I., Forss-Petter S., Kunze M., Zigman M., Berger J.;
RT   "X-linked adrenoleukodystrophy mice demonstrate abnormalities in
RT   cholesterol metabolism.";
RL   FEBS Lett. 579:5512-5516(2005).
RN   [9]
RP   REGION, AND MUTAGENESIS OF MET-67; ASN-68; ARG-69; VAL-70; PHE-71; LEU-72;
RP   GLN-73; ARG-74; LEU-75; LEU-76; TRP-77; LEU-78; LEU-79; ARG-80; LEU-81;
RP   LEU-82 AND PHE-83.
RX   PubMed=15781447; DOI=10.1074/jbc.m501750200;
RA   Halbach A., Lorenzen S., Landgraf C., Volkmer-Engert R., Erdmann R.,
RA   Rottensteiner H.;
RT   "Function of the PEX19-binding site of human adrenoleukodystrophy protein
RT   as targeting motif in man and yeast. PMP targeting is evolutionarily
RT   conserved.";
RL   J. Biol. Chem. 280:21176-21182(2005).
RN   [10]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=15682271; DOI=10.1007/s10038-004-0226-4;
RA   Guimaraes C.P., Sa-Miranda C., Azevedo J.E.;
RT   "Probing substrate-induced conformational alterations in
RT   adrenoleukodystrophy protein by proteolysis.";
RL   J. Hum. Genet. 50:99-105(2005).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=16946495; DOI=10.1248/bpb.29.1836;
RA   Morita M., Kurisu M., Kashiwayama Y., Yokota S., Imanaka T.;
RT   "ATP-binding and -hydrolysis activities of ALDP (ABCD1) and ALDRP (ABCD2),
RT   human peroxisomal ABC proteins, overexpressed in Sf21 cells.";
RL   Biol. Pharm. Bull. 29:1836-1842(2006).
RN   [12]
RP   INTERACTION WITH ABCD3, SUBUNIT, SUBCELLULAR LOCATION, AND REGION.
RX   PubMed=17609205; DOI=10.1074/jbc.m702122200;
RA   Hillebrand M., Verrier S.E., Ohlenbusch A., Schaefer A., Soeling H.D.,
RA   Wouters F.S., Gaertner J.;
RT   "Live cell FRET microscopy: homo- and heterodimerization of two human
RT   peroxisomal ABC transporters, the adrenoleukodystrophy protein (ALDP,
RT   ABCD1) and PMP70 (ABCD3).";
RL   J. Biol. Chem. 282:26997-27005(2007).
RN   [13]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=18757502; DOI=10.1096/fj.08-110866;
RA   van Roermund C.W., Visser W.F., Ijlst L., van Cruchten A., Boek M.,
RA   Kulik W., Waterham H.R., Wanders R.J.;
RT   "The human peroxisomal ABC half transporter ALDP functions as a homodimer
RT   and accepts acyl-CoA esters.";
RL   FASEB J. 22:4201-4208(2008).
RN   [14]
RP   FUNCTION, AND SUBSTRATE SPECIFICITY.
RX   PubMed=21145416; DOI=10.1016/j.bbalip.2010.11.010;
RA   van Roermund C.W., Visser W.F., Ijlst L., Waterham H.R., Wanders R.J.;
RT   "Differential substrate specificities of human ABCD1 and ABCD2 in
RT   peroxisomal fatty acid beta-oxidation.";
RL   Biochim. Biophys. Acta 1811:148-152(2011).
RN   [15]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=23671276; DOI=10.1074/jbc.m112.445445;
RA   Wiesinger C., Kunze M., Regelsberger G., Forss-Petter S., Berger J.;
RT   "Impaired very long-chain acyl-CoA beta-oxidation in human X-linked
RT   adrenoleukodystrophy fibroblasts is a direct consequence of ABCD1
RT   transporter dysfunction.";
RL   J. Biol. Chem. 288:19269-19279(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-733, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-733, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [21]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=29397936; DOI=10.1016/j.bbrc.2018.01.153;
RA   Okamoto T., Kawaguchi K., Watanabe S., Agustina R., Ikejima T., Ikeda K.,
RA   Nakano M., Morita M., Imanaka T.;
RT   "Characterization of human ATP-binding cassette protein subfamily D
RT   reconstituted into proteoliposomes.";
RL   Biochem. Biophys. Res. Commun. 496:1122-1127(2018).
RN   [22]
RP   CATALYTIC ACTIVITY, FUNCTION, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   LYS-513.
RX   PubMed=33500543; DOI=10.1038/s41598-021-81949-3;
RA   Kawaguchi K., Mukai E., Watanabe S., Yamashita A., Morita M., So T.,
RA   Imanaka T.;
RT   "Acyl-CoA thioesterase activity of peroxisomal ABC protein ABCD1 is
RT   required for the transport of very long-chain acyl-CoA into peroxisomes.";
RL   Sci. Rep. 11:2192-2192(2021).
RN   [23]
RP   VARIANT ALD LYS-291.
RX   PubMed=7904210; DOI=10.1093/hmg/2.11.1949;
RA   Cartier N., Sarde C.-O., Douar A.-M., Mosser J., Mandel J.-L., Aubourg P.;
RT   "Abnormal messenger RNA expression and a missense mutation in patients with
RT   X-linked adrenoleukodystrophy.";
RL   Hum. Mol. Genet. 2:1949-1951(1993).
RN   [24]
RP   VARIANTS ALD SER-148; ASP-174; ARG-266; GLN-401; TRP-418 AND PHE-515.
RX   PubMed=7849723; DOI=10.1093/hmg/3.10.1903;
RA   Fuchs S., Sarde C.-O., Wedemann H., Schwinger E., Mandel J.-L., Gal A.;
RT   "Missense mutations are frequent in the gene for X-chromosomal
RT   adrenoleukodystrophy (ALD).";
RL   Hum. Mol. Genet. 3:1903-1905(1994).
RN   [25]
RP   VARIANTS ALD TRP-518; LEU-606; CYS-617 AND HIS-617.
RX   PubMed=8040304; DOI=10.1172/jci117363;
RA   Fanen P., Guidoux S., Sarde C.-O., Mandel J.-L., Goossens M., Aubourg P.;
RT   "Identification of mutations in the putative ATP-binding domain of the
RT   adrenoleukodystrophy gene.";
RL   J. Clin. Invest. 94:516-520(1994).
RN   [26]
RP   VARIANTS ALD CYS-104; ASN-149; PRO-152; HIS-163; HIS-194; PRO-220; ARG-266;
RP   HIS-389; GLY-609; LYS-609; CYS-617 AND TRP-660.
RX   PubMed=7825602;
RA   Ligtenberg M.J.L., Kemp S., Sarde C.-O., van Geel B.M., Kleijer W.J.,
RA   Barth P.G., Mandel J.-L., van Oost B.A., Bolhuis P.A.;
RT   "Spectrum of mutations in the gene encoding the adrenoleukodystrophy
RT   protein.";
RL   Am. J. Hum. Genet. 56:44-50(1995).
RN   [27]
RP   VARIANTS ALD HIS-104; GLU-178; GLY-528 DEL AND LEU-560.
RX   PubMed=7717396;
RA   Braun A., Ambach H., Kammerer S., Rolinski B., Stoeckler S., Rabl W.,
RA   Gaertner J., Zierz S., Roscher A.A.;
RT   "Mutations in the gene for X-linked adrenoleukodystrophy in patients with
RT   different clinical phenotypes.";
RL   Am. J. Hum. Genet. 56:854-861(1995).
RN   [28]
RP   VARIANTS ALD GLU-276; ASP-291; GLU-291 DEL; PRO-342; HIS-389; GLN-401;
RP   GLN-591; LEU-606; HIS-617; THR-626; HIS-629 AND TRP-660.
RX   PubMed=7668254;
RA   Watkins P.A., Gould S.J., Smith M.A., Braiterman L.T., Wei H.M., Kok F.,
RA   Moser A.B., Moser H.W., Smith K.D.;
RT   "Altered expression of ALDP in X-linked adrenoleukodystrophy.";
RL   Am. J. Hum. Genet. 57:292-301(1995).
RN   [29]
RP   VARIANT ALD SER-174.
RX   PubMed=7860075; DOI=10.1007/bf00209412;
RA   Barcelo A., Giros M., Sarde C.O., Pintos G., Mandel J.L., Pampols T.,
RA   Estivill X.;
RT   "De novo missense mutation Y174S in exon 1 of the adrenoleukodystrophy
RT   (ALD) gene.";
RL   Hum. Genet. 95:235-237(1995).
RN   [30]
RP   VARIANTS ALD CYS-104; THR-141; PRO-182; TRP-277; HIS-389; SER-512; LYS-566;
RP   LEU-606; HIS-617 AND TRP-660.
RX   PubMed=7581394; DOI=10.1002/humu.1380060203;
RA   Kok F., Neumann S., Sarde C.-O., Zheng S., Wu K.-H., Wei H.-M., Bergin J.,
RA   Watkins P.A., Gould S., Sack G., Moser H., Mandel J.-L., Smith K.D.;
RT   "Mutational analysis of patients with X-linked adrenoleukodystrophy.";
RL   Hum. Mutat. 6:104-115(1995).
RN   [31]
RP   VARIANTS ALD SER-512; LEU-534 AND TRP-660.
RX   PubMed=7561948; DOI=10.1016/0022-510x(95)00047-6;
RA   Yasutake T., Yamada T., Furuya H., Shinnoh N., Goto I., Kobayashi T.;
RT   "Molecular analysis of X-linked adrenoleukodystrophy patients.";
RL   J. Neurol. Sci. 131:58-64(1995).
RN   [32]
RP   VARIANTS ALD LEU-98; ILE-105; TRP-108; ARG-116; SER-148; VAL-200; GLY-221;
RP   LEU-263; THR-294; SER-512; TRP-518; TRP-522; ARG-560; PRO-606 AND TRP-660.
RX   PubMed=8651290;
RA   Feigenbaum V., Lombard-Platet G., Guidoux S., Sarde C.-O., Mandel J.-L.,
RA   Aubourg P.;
RT   "Mutational and protein analysis of patients and heterozygous women with X-
RT   linked adrenoleukodystrophy.";
RL   Am. J. Hum. Genet. 58:1135-1144(1996).
RN   [33]
RP   VARIANTS ALD PRO-107; ASP-174; PRO-211; MET-254; ARG-277; GLY-389; GLN-401;
RP   TRP-418; LYS-609; CYS-617 AND GLY-617.
RX   PubMed=8566952; DOI=10.1007/bf02265264;
RA   Krasemann E.W., Meier V., Korenke G.C., Hunneman D.H., Hanefeld F.;
RT   "Identification of mutations in the ALD-gene of 20 families with
RT   adrenoleukodystrophy/adrenomyeloneuropathy.";
RL   Hum. Genet. 97:194-197(1996).
RN   [34]
RP   VARIANT ALD ARG-679.
RX   PubMed=9452087; DOI=10.1002/humu.1380110166;
RA   Korenke G.C., Krasemann E., Meier V., Beuche W., Hunneman D.H.,
RA   Hanefeld F.;
RT   "First missense mutation (W679R) in exon 10 of the adrenoleukodystrophy
RT   gene in siblings with adrenomyeloneuropathy.";
RL   Hum. Mutat. Suppl. 1:S204-S206(1998).
RN   [35]
RP   VARIANT ALD PRO-322.
RX   PubMed=9584268; DOI=10.1023/a:1005399810735;
RA   Osaka H., Sekiguchi H., Inoue K., Ikuta K., Sakakihara Y., Oka A.,
RA   Onishi H., Miyakawa T., Suzuki K., Kimura S., Kosaka K., Matsuyama S.;
RT   "A novel mutation found in an adrenoleukodystrophy patient who underwent
RT   bone marrow transplantation.";
RL   J. Inherit. Metab. Dis. 21:162-166(1998).
RN   [36]
RP   VARIANTS ALD CYS-213 AND ILE-636, AND REVIEW.
RX   PubMed=9553942; DOI=10.1055/s-2007-973526;
RA   Gaertner J., Braun A., Holzinger A., Roerig P., Lenard H.G., Roscher A.A.;
RT   "Clinical and genetic aspects of X-linked adrenoleukodystrophy.";
RL   Neuropediatrics 29:3-13(1998).
RN   [37]
RP   VARIANTS ALD SER-148; ASN-200; ASP-214; ARG-266; LYS-271; CYS-296; TRP-401;
RP   VAL-507; GLN-518; SER-540; ARG-544; TRP-591; LEU-606 AND TRP-660.
RX   PubMed=10190819; DOI=10.1001/archneur.56.3.295;
RA   Takano H., Koike R., Onodera O., Sasaki R., Tsuji S.;
RT   "Mutational analysis and genotype-phenotype correlation of 29 unrelated
RT   Japanese patients with X-linked adrenoleukodystrophy.";
RL   Arch. Neurol. 56:295-300(1999).
RN   [38]
RP   VARIANTS ALD PRO-105; SER-143; SER-148; PRO-190; ASP-298; ARG-339; SER-529
RP   AND TYR-638.
RX   PubMed=10480364; DOI=10.1007/s004399900090;
RA   Wichers M., Kohler W., Brennemann W., Boese V., Sokolowski P.,
RA   Bidlingmaier F., Ludwig M.;
RT   "X-linked adrenomyeloneuropathy associated with 14 novel ALD-gene
RT   mutations: no correlation between type of mutation and age of onset.";
RL   Hum. Genet. 105:116-119(1999).
RN   [39]
RP   VARIANTS ALD LEU-108 AND SER-143.
RX   PubMed=10369742; DOI=10.1006/mcpr.1999.0232;
RA   Perusi C., Gomez-Lira M., Mottes M., Pignatti P.F., Bertini E., Cappa M.,
RA   Vigliani M.C., Schiffer D., Rizzuto N., Salviati A.;
RT   "Two novel missense mutations causing adrenoleukodystrophy in Italian
RT   patients.";
RL   Mol. Cell. Probes 13:179-182(1999).
RN   [40]
RP   VARIANT ALD PRO-552, AND REVIEW.
RX   PubMed=10227685; DOI=10.1023/a:1022535930009;
RA   Smith K.D., Kemp S., Braiterman L.T., Lu J.F., Wei H.M., Geraghty M.,
RA   Stetten G., Bergin J.S., Pevsner J., Watkins P.A.;
RT   "X-linked adrenoleukodystrophy: genes, mutations, and phenotypes.";
RL   Neurochem. Res. 24:521-535(1999).
RN   [41]
RP   VARIANTS ALD ARG-103; ARG-116; SER-152; CYS-174; TRP-189; THR-218; PRO-229;
RP   ASP-298; GLN-401; TRP-401; TRP-418; LEU-543; HIS-554; VAL-616; ARG-633 AND
RP   PRO-646.
RX   PubMed=10737980;
RX   DOI=10.1002/(sici)1098-1004(200004)15:4<348::aid-humu7>3.0.co;2-n;
RA   Lachtermacher M.B., Seuanez H.N., Moser A.B., Moser H.W., Smith K.D.;
RT   "Determination of 30 X-linked adrenoleukodystrophy mutations, including 15
RT   not previously described.";
RL   Hum. Mutat. 15:348-353(2000).
RN   [42]
RP   VARIANTS ALD GLN-401; TRP-418; LEU-543 AND ARG-556.
RX   PubMed=10980539;
RX   DOI=10.1002/1098-1004(200009)16:3<271::aid-humu15>3.0.co;2-d;
RA   Lira M.G., Mottes M., Pignatti P.F., Medica I., Uziel G., Cappa M.,
RA   Bertini E., Rizzuto N., Salviati A.;
RT   "Detection of mutations in the ALD gene (ABCD1) in seven Italian families:
RT   description of four novel mutations.";
RL   Hum. Mutat. 16:271-271(2000).
RN   [43]
RP   VARIANT ALD VAL-GLY-GLN-300 INS.
RX   PubMed=11810273; DOI=10.1007/s00439-001-0632-z;
RA   Guimaraes C.P., Lemos M., Menezes I., Coelho T., Sa-Miranda C.,
RA   Azevedo J.E.;
RT   "Characterisation of two mutations in the ABCD1 gene leading to low levels
RT   of normal ALDP.";
RL   Hum. Genet. 109:616-622(2001).
RN   [44]
RP   VARIANTS ALD LEU-98; ASP-99; GLU-217; GLN-518; ASP-608; ILE-633 AND
RP   PRO-660, VARIANT THR-13, CHARACTERIZATION OF VARIANT ALD GLU-217, AND
RP   CHARACTERIZATION OF VARIANT THR-13.
RX   PubMed=11438993; DOI=10.1002/humu.1149;
RA   Dvorakova L., Storkanova G., Unterrainer G., Hujova J., Kmoch S., Zeman J.,
RA   Hrebicek M., Berger J.;
RT   "Eight novel ABCD1 gene mutations and three polymorphisms in patients with
RT   X-linked adrenoleukodystrophy: the first polymorphism causing an amino acid
RT   exchange.";
RL   Hum. Mutat. 18:52-60(2001).
RN   [45]
RP   VARIANTS ALD LYS-90; CYS-113; PRO-113; LEU-152; PRO-161; PRO-163; LYS-198;
RP   GLU-224; TRP-274; CYS-280; PRO-285; MET-336; ASP-343; SER-560; PRO-591;
RP   ASP-626; GLY-630; TYR-631; ILE-632; MET-635; PRO-654; ASP-667; ILE-668 AND
RP   MET-693.
RX   PubMed=11748843; DOI=10.1002/humu.1227;
RA   Kemp S., Pujol A., Waterham H.R., van Geel B.M., Boehm C.D., Raymond G.V.,
RA   Cutting G.R., Wanders R.J., Moser H.W.;
RT   "ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database:
RT   role in diagnosis and clinical correlations.";
RL   Hum. Mutat. 18:499-515(2001).
RN   [46]
RP   INVOLVEMENT IN CONTIGUOUS ABCD1/DXS1375E DELETION SYNDROME.
RX   PubMed=11992258; DOI=10.1086/340849;
RA   Corzo D., Gibson W., Johnson K., Mitchell G., LePage G., Cox G.F.,
RA   Casey R., Zeiss C., Tyson H., Cutting G.R., Raymond G.V., Smith K.D.,
RA   Watkins P.A., Moser A.B., Moser H.W., Steinberg S.J.;
RT   "Contiguous deletion of the X-linked adrenoleukodystrophy gene (ABCD1) and
RT   DXS1357E: a novel neonatal phenotype similar to peroxisomal biogenesis
RT   disorders.";
RL   Am. J. Hum. Genet. 70:1520-1531(2002).
RN   [47]
RP   RETRACTED PAPER.
RX   PubMed=15643618; DOI=10.1002/humu.9303;
RA   Montagna G., Di Biase A., Cappa M., Melone M.A.B., Piantadosi C.,
RA   Colabianchi D., Patrono C., Attori L., Cannelli N., Cotrufo R., Salvati S.,
RA   Santorelli F.M.;
RT   "Identification of seven novel mutations in ABCD1 by a DHPLC-based assay in
RT   Italian patients with X-linked adrenoleukodystrophy.";
RL   Hum. Mutat. 25:222-222(2005).
RN   [48]
RP   RETRACTION NOTICE OF PUBMED:15643618.
RX   PubMed=34337821; DOI=10.1002/humu.24093;
RA   Montagna G., Di Biase A., Cappa M., Melone M.A.B., Piantadosi C.,
RA   Colabianchi D., Patrono C., Attori L., Cannelli N., Cotrufo R., Salvati S.,
RA   Santorelli F.M.;
RL   Hum. Mutat. 41:1830-1830(2020).
RN   [49]
RP   VARIANTS ALD GLN-401; PRO-516; LEU-560; PRO-606 AND GLN-660.
RX   PubMed=21889498; DOI=10.1016/j.cca.2011.08.026;
RA   Shukla P., Gupta N., Gulati S., Ghosh M., Vasisht S., Sharma R.,
RA   Gupta A.K., Kalra V., Kabra M.;
RT   "Molecular analysis of ABCD1 gene in Indian patients with X-linked
RT   adrenoleukodystrophy.";
RL   Clin. Chim. Acta 412:2289-2295(2011).
RN   [50]
RP   VARIANTS ALD LEU-139 DEL; ARG-198; ARG-266; GLU-266; TRP-401; GLN-518;
RP   PHE-523; CYS-540; LEU-560; PRO-606; HIS-617; THR-626; PRO-632; ARG-633;
RP   LYS-640 AND ASP-677.
RX   PubMed=21700483; DOI=10.1016/j.ymgme.2011.05.016;
RA   Wang Y., Busin R., Reeves C., Bezman L., Raymond G., Toomer C.J.,
RA   Watkins P.A., Snowden A., Moser A., Naidu S., Bibat G., Hewson S., Tam K.,
RA   Clarke J.T., Charnas L., Stetten G., Karczeski B., Cutting G.,
RA   Steinberg S.;
RT   "X-linked adrenoleukodystrophy: ABCD1 de novo mutations and mosaicism.";
RL   Mol. Genet. Metab. 104:160-166(2011).
RN   [51]
RP   VARIANTS ALD LEU-108; SER-148; ASP-214; PRO-254; ARG-266; LYS-271; ARG-277;
RP   TRP-401; GLN-518; TRP-518; SER-540; ARG-544; LEU-560; LYS-609 AND TRP-660.
RX   PubMed=20661612; DOI=10.1007/s10048-010-0253-6;
RA   Matsukawa T., Asheuer M., Takahashi Y., Goto J., Suzuki Y., Shimozawa N.,
RA   Takano H., Onodera O., Nishizawa M., Aubourg P., Tsuji S.;
RT   "Identification of novel SNPs of ABCD1, ABCD2, ABCD3, and ABCD4 genes in
RT   patients with X-linked adrenoleukodystrophy (ALD) based on comprehensive
RT   resequencing and association studies with ALD phenotypes.";
RL   Neurogenetics 12:41-50(2011).
RN   [52]
RP   VARIANTS ALD ARG-266; LYS-302; GLN-401; TRP-591; PRO-606; LYS-609 AND
RP   GLN-660.
RX   PubMed=21966424; DOI=10.1371/journal.pone.0025094;
RA   Kumar N., Taneja K.K., Kalra V., Behari M., Aneja S., Bansal S.K.;
RT   "Genomic profiling identifies novel mutations and SNPs in ABCD1 gene: a
RT   molecular, biochemical and clinical analysis of X-ALD cases in India.";
RL   PLoS ONE 6:e25094-e25094(2011).
RN   [53]
RP   VARIANT ALD ASP-95.
RX   PubMed=23651979; DOI=10.1159/000346680;
RA   Kallabi F., Hadj Salem I., Ben Salah G., Ben Turkia H., Ben Chehida A.,
RA   Tebib N., Fakhfakh F., Kamoun H.;
RT   "Molecular characterization of X-linked adrenoleukodystrophy in a Tunisian
RT   family: identification of a novel missense mutation in the ABCD1 gene.";
RL   Neurodegener. Dis. 12:207-211(2013).
RN   [54]
RP   VARIANT ALD PRO-316.
RX   PubMed=26686776; DOI=10.1016/j.cca.2015.12.014;
RA   Kallabi F., Ellouz E., Tabebi M., Ben Salah G., Kaabechi N., Keskes L.,
RA   Triki C., Kamoun H.;
RT   "Phenotypic variability in a Tunisian family with X-linked
RT   adrenoleukodystrophy caused by the p.Gln316Pro novel mutation.";
RL   Clin. Chim. Acta 453:141-146(2015).
RN   [55]
RP   VARIANT ALD SER-174.
RX   PubMed=28456143;
RA   Horikawa Y., Enya M., Yoshikura N., Kitagawa J., Takashima S.,
RA   Shimozawa N., Takeda J.;
RT   "A first case of adrenomyeloneuropathy with mutation Y174S of the
RT   adrenoleukodystrophy gene.";
RL   Neuroendocrinol. Lett. 38:13-18(2017).
CC   -!- FUNCTION: ATP-dependent transporter of the ATP-binding cassette (ABC)
CC       family involved in the transport of very long chain fatty acid (VLCFA)-
CC       CoA from the cytosol to the peroxisome lumen (PubMed:11248239,
CC       PubMed:15682271, PubMed:16946495, PubMed:18757502, PubMed:21145416,
CC       PubMed:23671276, PubMed:29397936, PubMed:33500543). Coupled to the ATP-
CC       dependent transporter activity has also a fatty acyl-CoA thioesterase
CC       activity (ACOT) and hydrolyzes VLCFA-CoA into VLCFA prior their ATP-
CC       dependent transport into peroxisomes, the ACOT activity is essential
CC       during this transport process (PubMed:33500543, PubMed:29397936). Thus,
CC       plays a role in regulation of VLCFAs and energy metabolism namely, in
CC       the degradation and biosynthesis of fatty acids by beta-oxidation,
CC       mitochondrial function and microsomal fatty acid elongation
CC       (PubMed:23671276, PubMed:21145416). Involved in several processes;
CC       namely, controls the active myelination phase by negatively regulating
CC       the microsomal fatty acid elongation activity and may also play a role
CC       in axon and myelin maintenance. Controls also the cellular response to
CC       oxidative stress by regulating mitochondrial functions such as
CC       mitochondrial oxidative phosphorylation and depolarization. And finally
CC       controls the inflammatory response by positively regulating peroxisomal
CC       beta-oxidation of VLCFAs (By similarity).
CC       {ECO:0000250|UniProtKB:P48410, ECO:0000269|PubMed:11248239,
CC       ECO:0000269|PubMed:15682271, ECO:0000269|PubMed:16946495,
CC       ECO:0000269|PubMed:18757502, ECO:0000269|PubMed:21145416,
CC       ECO:0000269|PubMed:23671276, ECO:0000269|PubMed:29397936,
CC       ECO:0000269|PubMed:33500543}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a very long-chain fatty acyl-CoA + H2O = a very long-chain
CC         fatty acid + CoA + H(+); Xref=Rhea:RHEA:67072, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:57287, ChEBI:CHEBI:58950,
CC         ChEBI:CHEBI:138261; Evidence={ECO:0000269|PubMed:29397936,
CC         ECO:0000269|PubMed:33500543};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67073;
CC         Evidence={ECO:0000305|PubMed:33500543};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a very long-chain fatty acid(in) + ATP + H2O = a very long-
CC         chain fatty acid(out) + ADP + H(+) + phosphate; Xref=Rhea:RHEA:67080,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:58950, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:11248239, ECO:0000269|PubMed:29397936,
CC         ECO:0000269|PubMed:33500543, ECO:0000305|PubMed:16946495,
CC         ECO:0000305|PubMed:21145416, ECO:0000305|PubMed:23671276};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67081;
CC         Evidence={ECO:0000305|PubMed:33500543};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + tetracosanoyl-CoA = CoA + H(+) + tetracosanoate;
CC         Xref=Rhea:RHEA:40787, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:31014, ChEBI:CHEBI:57287, ChEBI:CHEBI:65052;
CC         Evidence={ECO:0000269|PubMed:33500543};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40788;
CC         Evidence={ECO:0000305|PubMed:33500543};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O + tetracosanoate(in) = ADP + H(+) + phosphate +
CC         tetracosanoate(out); Xref=Rhea:RHEA:67088, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:31014,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000305|PubMed:21145416};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67089;
CC         Evidence={ECO:0000305|PubMed:33500543};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + hexacosanoyl-CoA = CoA + H(+) + hexacosanoate;
CC         Xref=Rhea:RHEA:40791, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:31013, ChEBI:CHEBI:57287, ChEBI:CHEBI:64868;
CC         Evidence={ECO:0000269|PubMed:33500543};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40792;
CC         Evidence={ECO:0000305|PubMed:33500543};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O + hexacosanoate(in) = ADP + H(+) +
CC         hexacosanoate(out) + phosphate; Xref=Rhea:RHEA:67084,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:31013, ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000305|PubMed:21145416, ECO:0000305|PubMed:23671276};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67085;
CC         Evidence={ECO:0000305|PubMed:21145416};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=docosanoyl-CoA + H2O = CoA + docosanoate + H(+);
CC         Xref=Rhea:RHEA:40783, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:23858, ChEBI:CHEBI:57287, ChEBI:CHEBI:65059;
CC         Evidence={ECO:0000269|PubMed:33500543};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40784;
CC         Evidence={ECO:0000305|PubMed:33500543};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + docosanoate(in) + H2O = ADP + docosanoate(out) + H(+) +
CC         phosphate; Xref=Rhea:RHEA:67092, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:23858, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000305|PubMed:23671276};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67093;
CC         Evidence={ECO:0000305|PubMed:23671276};
CC   -!- ACTIVITY REGULATION: The cysteine-reactive reagent p-
CC       chloromercuribenzoic acid (pCMB) strongly decreased the ACOT activity.
CC       The serine esterase inhibitors phenylmethylsulfonyl fluoride (PMSF),
CC       diisopropylfluorophosphate (DFP) and bis-(4-nitrophenyl)phosphate
CC       (BNPP) moderately reduced the ACOT activity. The histidine-reacting
CC       reagent diethyl pyrocarbonate (DEPC) has no effect on the ACOT
CC       activity. {ECO:0000269|PubMed:33500543}.
CC   -!- SUBUNIT: Can form homodimers and heterodimers with ABCD2 and ABCD3.
CC       Dimerization is necessary to form an active transporter
CC       (PubMed:17609205, PubMed:10551832) (Probable). The minimal functional
CC       unit is a homodimer but the major oligomeric form in peroxisomal
CC       membrane is a homotetramer (By similarity). Forms heterotramers with
CC       ABCD2 (By similarity). Interacts with PEX19; facilitates ABCD1
CC       insertion into the peroxisome membrane (PubMed:10777694,
CC       PubMed:10704444). {ECO:0000250|UniProtKB:D3ZHR2,
CC       ECO:0000269|PubMed:10551832, ECO:0000269|PubMed:10704444,
CC       ECO:0000269|PubMed:10777694, ECO:0000269|PubMed:17609205,
CC       ECO:0000305|PubMed:18757502}.
CC   -!- INTERACTION:
CC       P33897; P33897: ABCD1; NbExp=2; IntAct=EBI-81045, EBI-81045;
CC       P33897; P28288: ABCD3; NbExp=2; IntAct=EBI-81045, EBI-80992;
CC       P33897; P40855: PEX19; NbExp=3; IntAct=EBI-81045, EBI-594747;
CC       P33897; P48410: Abcd1; Xeno; NbExp=2; IntAct=EBI-81045, EBI-81118;
CC   -!- SUBCELLULAR LOCATION: Peroxisome membrane {ECO:0000269|PubMed:10777694,
CC       ECO:0000269|PubMed:16946495, ECO:0000269|PubMed:17609205,
CC       ECO:0000269|PubMed:18757502, ECO:0000269|PubMed:29397936}; Multi-pass
CC       membrane protein {ECO:0000255}. Mitochondrion membrane
CC       {ECO:0000269|PubMed:16946495}; Multi-pass membrane protein. Lysosome
CC       membrane {ECO:0000269|PubMed:16946495}; Multi-pass membrane protein.
CC       Endoplasmic reticulum membrane {ECO:0000269|PubMed:16946495}; Multi-
CC       pass membrane protein.
CC   -!- INDUCTION: Up-regulated by degradation or export of cholesterol.
CC       {ECO:0000269|PubMed:16213491}.
CC   -!- DOMAIN: The NH2-terminal transmembrane domaine (TMD) is involved in the
CC       recognition of substrates, and undergoes a conformational change upon
CC       ATP binding to the COOH-terminal nucleotide binding domain (NBD).
CC       {ECO:0000269|PubMed:15682271}.
CC   -!- PTM: Tyrosine-phosphorylated. {ECO:0000250|UniProtKB:D3ZHR2}.
CC   -!- DISEASE: Adrenoleukodystrophy (ALD) [MIM:300100]: A peroxisomal
CC       metabolic disorder characterized by progressive multifocal
CC       demyelination of the central nervous system and by peripheral adrenal
CC       insufficiency (Addison disease). It results in mental deterioration,
CC       corticospinal tract dysfunction, and cortical blindness. Different
CC       clinical manifestations exist like: cerebral childhood ALD (CALD),
CC       adult cerebral ALD (ACALD), adrenomyeloneuropathy (AMN) and 'Addison
CC       disease only' (ADO) phenotype. {ECO:0000269|PubMed:10190819,
CC       ECO:0000269|PubMed:10227685, ECO:0000269|PubMed:10369742,
CC       ECO:0000269|PubMed:10480364, ECO:0000269|PubMed:10551832,
CC       ECO:0000269|PubMed:10737980, ECO:0000269|PubMed:10980539,
CC       ECO:0000269|PubMed:11248239, ECO:0000269|PubMed:11438993,
CC       ECO:0000269|PubMed:11748843, ECO:0000269|PubMed:11810273,
CC       ECO:0000269|PubMed:20661612, ECO:0000269|PubMed:21700483,
CC       ECO:0000269|PubMed:21889498, ECO:0000269|PubMed:21966424,
CC       ECO:0000269|PubMed:23651979, ECO:0000269|PubMed:26686776,
CC       ECO:0000269|PubMed:28456143, ECO:0000269|PubMed:7561948,
CC       ECO:0000269|PubMed:7581394, ECO:0000269|PubMed:7668254,
CC       ECO:0000269|PubMed:7717396, ECO:0000269|PubMed:7825602,
CC       ECO:0000269|PubMed:7849723, ECO:0000269|PubMed:7860075,
CC       ECO:0000269|PubMed:7904210, ECO:0000269|PubMed:8040304,
CC       ECO:0000269|PubMed:8566952, ECO:0000269|PubMed:8651290,
CC       ECO:0000269|PubMed:9452087, ECO:0000269|PubMed:9553942,
CC       ECO:0000269|PubMed:9584268}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=The promoter region of ABCD1 is deleted in the chromosome
CC       Xq28 deletion syndrome which involves ABCD1 and the neighboring gene
CC       BCAP31. {ECO:0000269|PubMed:11992258}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCD family.
CC       Peroxisomal fatty acyl CoA transporter (TC 3.A.1.203) subfamily.
CC       {ECO:0000305}.
CC   -!- CAUTION: Variants Trp-88, Cys-152, Cys-181, Ser-343, Pro-503, Arg-514
CC       and His-554 have original been associated with ALD. However this paper
CC       was retracted due to inconsistencies in a confirmation immunoblot that
CC       could not be validated from the originally published data.
CC       {ECO:0000305|PubMed:15643618, ECO:0000305|PubMed:34337821}.
CC   -!- WEB RESOURCE: Name=X-ALD gene mutation database;
CC       URL="https://adrenoleukodystrophy.info/";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC proteins;
CC       URL="http://abcm2.hegelab.org/search";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z21876; CAA79922.1; -; mRNA.
DR   EMBL; Z31348; CAA83230.1; -; Genomic_DNA.
DR   EMBL; Z31006; CAA83230.1; JOINED; Genomic_DNA.
DR   EMBL; Z31007; CAA83230.1; JOINED; Genomic_DNA.
DR   EMBL; Z31008; CAA83230.1; JOINED; Genomic_DNA.
DR   EMBL; Z31009; CAA83230.1; JOINED; Genomic_DNA.
DR   EMBL; Z31010; CAA83230.1; JOINED; Genomic_DNA.
DR   EMBL; U52111; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015541; AAH15541.1; -; mRNA.
DR   EMBL; BC025358; AAH25358.1; -; mRNA.
DR   CCDS; CCDS14728.1; -.
DR   PIR; G02500; G02500.
DR   RefSeq; NP_000024.2; NM_000033.3.
DR   PDB; 7RR9; EM; 3.50 A; A/B=1-745.
DR   PDB; 7RRA; EM; 4.40 A; A/B=1-745.
DR   PDB; 7SHM; EM; 3.14 A; A/B=2-745.
DR   PDB; 7SHN; EM; 3.10 A; A/B=2-686.
DR   PDB; 7VR1; EM; 3.40 A; A/B=1-745.
DR   PDB; 7VWC; EM; 3.53 A; A/B=65-745.
DR   PDB; 7VX8; EM; 2.80 A; A/B=65-745.
DR   PDB; 7VZB; EM; 3.59 A; A/B=65-745.
DR   PDB; 7X07; EM; 3.78 A; A/B=1-745.
DR   PDB; 7X0T; EM; 3.30 A; A/B=1-745.
DR   PDB; 7X0Z; EM; 2.96 A; A/B=1-745.
DR   PDB; 7X1W; EM; 3.30 A; A/B=1-745.
DR   PDB; 7XEC; EM; 3.34 A; A/B=1-745.
DR   PDB; 7YRQ; EM; 3.35 A; A/B=1-745.
DR   PDBsum; 7RR9; -.
DR   PDBsum; 7RRA; -.
DR   PDBsum; 7SHM; -.
DR   PDBsum; 7SHN; -.
DR   PDBsum; 7VR1; -.
DR   PDBsum; 7VWC; -.
DR   PDBsum; 7VX8; -.
DR   PDBsum; 7VZB; -.
DR   PDBsum; 7X07; -.
DR   PDBsum; 7X0T; -.
DR   PDBsum; 7X0Z; -.
DR   PDBsum; 7X1W; -.
DR   PDBsum; 7XEC; -.
DR   PDBsum; 7YRQ; -.
DR   AlphaFoldDB; P33897; -.
DR   EMDB; EMD-24656; -.
DR   EMDB; EMD-24657; -.
DR   EMDB; EMD-25130; -.
DR   EMDB; EMD-25131; -.
DR   EMDB; EMD-32096; -.
DR   EMDB; EMD-33155; -.
DR   EMDB; EMD-34064; -.
DR   SMR; P33897; -.
DR   BioGRID; 106717; 79.
DR   IntAct; P33897; 27.
DR   MINT; P33897; -.
DR   STRING; 9606.ENSP00000218104; -.
DR   SwissLipids; SLP:000000458; -.
DR   TCDB; 3.A.1.203.3; the atp-binding cassette (abc) superfamily.
DR   GlyCosmos; P33897; 1 site, No reported glycans.
DR   GlyGen; P33897; 1 site.
DR   iPTMnet; P33897; -.
DR   PhosphoSitePlus; P33897; -.
DR   SwissPalm; P33897; -.
DR   BioMuta; ABCD1; -.
DR   DMDM; 67476960; -.
DR   EPD; P33897; -.
DR   jPOST; P33897; -.
DR   MassIVE; P33897; -.
DR   MaxQB; P33897; -.
DR   PaxDb; 9606-ENSP00000218104; -.
DR   PeptideAtlas; P33897; -.
DR   ProteomicsDB; 54928; -.
DR   Pumba; P33897; -.
DR   Antibodypedia; 30940; 482 antibodies from 35 providers.
DR   DNASU; 215; -.
DR   Ensembl; ENST00000218104.6; ENSP00000218104.3; ENSG00000101986.12.
DR   GeneID; 215; -.
DR   KEGG; hsa:215; -.
DR   MANE-Select; ENST00000218104.6; ENSP00000218104.3; NM_000033.4; NP_000024.2.
DR   UCSC; uc004fif.2; human.
DR   AGR; HGNC:61; -.
DR   CTD; 215; -.
DR   DisGeNET; 215; -.
DR   GeneCards; ABCD1; -.
DR   GeneReviews; ABCD1; -.
DR   HGNC; HGNC:61; ABCD1.
DR   HPA; ENSG00000101986; Low tissue specificity.
DR   MalaCards; ABCD1; -.
DR   MIM; 300100; phenotype.
DR   MIM; 300371; gene.
DR   neXtProt; NX_P33897; -.
DR   OpenTargets; ENSG00000101986; -.
DR   Orphanet; 139399; Adrenomyeloneuropathy.
DR   Orphanet; 369942; CADDS.
DR   Orphanet; 388; Hirschsprung disease.
DR   Orphanet; 139396; X-linked cerebral adrenoleukodystrophy.
DR   PharmGKB; PA24396; -.
DR   VEuPathDB; HostDB:ENSG00000101986; -.
DR   eggNOG; KOG0064; Eukaryota.
DR   GeneTree; ENSGT00950000182955; -.
DR   HOGENOM; CLU_007587_1_1_1; -.
DR   InParanoid; P33897; -.
DR   OMA; CHRTSLW; -.
DR   OrthoDB; 7698at2759; -.
DR   PhylomeDB; P33897; -.
DR   TreeFam; TF105205; -.
DR   BRENDA; 7.6.2.4; 2681.
DR   PathwayCommons; P33897; -.
DR   Reactome; R-HSA-1369062; ABC transporters in lipid homeostasis.
DR   Reactome; R-HSA-2046105; Linoleic acid (LA) metabolism.
DR   Reactome; R-HSA-2046106; alpha-linolenic acid (ALA) metabolism.
DR   Reactome; R-HSA-390247; Beta-oxidation of very long chain fatty acids.
DR   Reactome; R-HSA-5684045; Defective ABCD1 causes ALD.
DR   Reactome; R-HSA-9603798; Class I peroxisomal membrane protein import.
DR   SignaLink; P33897; -.
DR   BioGRID-ORCS; 215; 23 hits in 782 CRISPR screens.
DR   ChiTaRS; ABCD1; human.
DR   GeneWiki; ABCD1; -.
DR   GenomeRNAi; 215; -.
DR   Pharos; P33897; Tbio.
DR   PRO; PR:P33897; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P33897; Protein.
DR   Bgee; ENSG00000101986; Expressed in ileal mucosa and 130 other cell types or tissues.
DR   ExpressionAtlas; P33897; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0031966; C:mitochondrial membrane; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005778; C:peroxisomal membrane; IDA:UniProtKB.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0015607; F:ABC-type fatty-acyl-CoA transporter activity; IDA:UniProtKB.
DR   GO; GO:0047617; F:acyl-CoA hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0043531; F:ADP binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB.
DR   GO; GO:0042626; F:ATPase-coupled transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005324; F:long-chain fatty acid transporter activity; IGI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0036109; P:alpha-linolenic acid metabolic process; TAS:Reactome.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; IDA:UniProtKB.
DR   GO; GO:0030497; P:fatty acid elongation; ISS:UniProtKB.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB.
DR   GO; GO:0043651; P:linoleic acid metabolic process; TAS:Reactome.
DR   GO; GO:0042758; P:long-chain fatty acid catabolic process; IMP:UniProtKB.
DR   GO; GO:0015910; P:long-chain fatty acid import into peroxisome; IGI:UniProtKB.
DR   GO; GO:0043217; P:myelin maintenance; ISS:UniProtKB.
DR   GO; GO:1900016; P:negative regulation of cytokine production involved in inflammatory response; ISS:UniProtKB.
DR   GO; GO:1903427; P:negative regulation of reactive oxygen species biosynthetic process; ISS:UniProtKB.
DR   GO; GO:1990535; P:neuron projection maintenance; ISS:UniProtKB.
DR   GO; GO:0015919; P:peroxisomal membrane transport; NAS:UniProtKB.
DR   GO; GO:0007031; P:peroxisome organization; IDA:UniProtKB.
DR   GO; GO:0032000; P:positive regulation of fatty acid beta-oxidation; IMP:UniProtKB.
DR   GO; GO:2001280; P:positive regulation of unsaturated fatty acid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:1900407; P:regulation of cellular response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:0031998; P:regulation of fatty acid beta-oxidation; ISS:UniProtKB.
DR   GO; GO:0051900; P:regulation of mitochondrial depolarization; ISS:UniProtKB.
DR   GO; GO:0002082; P:regulation of oxidative phosphorylation; ISS:UniProtKB.
DR   GO; GO:0055092; P:sterol homeostasis; ISS:UniProtKB.
DR   GO; GO:0042760; P:very long-chain fatty acid catabolic process; IDA:UniProtKB.
DR   GO; GO:0000038; P:very long-chain fatty acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0036113; P:very long-chain fatty-acyl-CoA catabolic process; IMP:UniProtKB.
DR   CDD; cd03223; ABCD_peroxisomal_ALDP; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR036640; ABC1_TM_sf.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR005283; FA_transporter.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   NCBIfam; TIGR00954; 3a01203; 1.
DR   PANTHER; PTHR11384:SF21; ATP-BINDING CASSETTE SUB-FAMILY D MEMBER 1; 1.
DR   PANTHER; PTHR11384; ATP-BINDING CASSETTE, SUB-FAMILY D MEMBER; 1.
DR   Pfam; PF06472; ABC_membrane_2; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF90123; ABC transporter transmembrane region; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS50929; ABC_TM1F; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
DR   Genevisible; P33897; HS.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Disease variant; Endoplasmic reticulum;
KW   Glycoprotein; Hydrolase; Lysosome; Membrane; Mitochondrion;
KW   Nucleotide-binding; Peroxisome; Phosphoprotein; Reference proteome;
KW   Translocase; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..745
FT                   /note="ATP-binding cassette sub-family D member 1"
FT                   /id="PRO_0000093304"
FT   TRANSMEM        92..112
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TRANSMEM        131..151
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TRANSMEM        238..258
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TRANSMEM        333..353
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   TRANSMEM        473..493
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   DOMAIN          94..386
FT                   /note="ABC transmembrane type-1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   DOMAIN          474..700
FT                   /note="ABC transporter"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00434"
FT   REGION          67..186
FT                   /note="Interaction with PEX19"
FT                   /evidence="ECO:0000269|PubMed:10777694"
FT   REGION          67..84
FT                   /note="PEX19 binding site and required for peroxisomal
FT                   targeting"
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   REGION          658..745
FT                   /note="Required for homodimerization"
FT                   /evidence="ECO:0000269|PubMed:17609205"
FT   BINDING         507..514
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00434"
FT   MOD_RES         733
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976"
FT   CARBOHYD        214
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         13
FT                   /note="N -> T (does not affect fatty acid beta-oxidation;
FT                   dbSNP:rs183021839)"
FT                   /evidence="ECO:0000269|PubMed:11438993"
FT                   /id="VAR_013340"
FT   VARIANT         90
FT                   /note="E -> K (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009349"
FT   VARIANT         95
FT                   /note="A -> D (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:23651979"
FT                   /id="VAR_075284"
FT   VARIANT         98
FT                   /note="S -> L (in ALD; CALD type; dbSNP:rs1557052294)"
FT                   /evidence="ECO:0000269|PubMed:11438993,
FT                   ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000024"
FT   VARIANT         99
FT                   /note="A -> D (in ALD; AMN-type)"
FT                   /evidence="ECO:0000269|PubMed:11438993"
FT                   /id="VAR_013341"
FT   VARIANT         103
FT                   /note="S -> R (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10737980"
FT                   /id="VAR_009350"
FT   VARIANT         104
FT                   /note="R -> C (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:7581394,
FT                   ECO:0000269|PubMed:7825602"
FT                   /id="VAR_000025"
FT   VARIANT         104
FT                   /note="R -> H (in ALD; ADO-type; dbSNP:rs1557052302)"
FT                   /evidence="ECO:0000269|PubMed:7717396"
FT                   /id="VAR_000026"
FT   VARIANT         105
FT                   /note="T -> I (in ALD; ADO-type)"
FT                   /evidence="ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000027"
FT   VARIANT         105
FT                   /note="T -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10480364"
FT                   /id="VAR_009351"
FT   VARIANT         107
FT                   /note="L -> P (in ALD; ALD/AMN/ADO-types and asymptomatic;
FT                   dbSNP:rs1569540688)"
FT                   /evidence="ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000028"
FT   VARIANT         108
FT                   /note="S -> L (in ALD; dbSNP:rs2091705631)"
FT                   /evidence="ECO:0000269|PubMed:10369742,
FT                   ECO:0000269|PubMed:20661612"
FT                   /id="VAR_009352"
FT   VARIANT         108
FT                   /note="S -> W (in ALD; CALD and AMN-types)"
FT                   /evidence="ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000029"
FT   VARIANT         113
FT                   /note="R -> C (in ALD; dbSNP:rs1557052306)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009353"
FT   VARIANT         113
FT                   /note="R -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013342"
FT   VARIANT         116
FT                   /note="G -> R (in ALD; CALD-type; dbSNP:rs398123110)"
FT                   /evidence="ECO:0000269|PubMed:10737980,
FT                   ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000030"
FT   VARIANT         138..141
FT                   /note="Missing (in ALD; ALD-type; dbSNP:rs1557052351)"
FT                   /evidence="ECO:0000269|PubMed:10227685"
FT                   /id="VAR_000032"
FT   VARIANT         139
FT                   /note="Missing (in ALD; dbSNP:rs1557052351)"
FT                   /evidence="ECO:0000269|PubMed:21700483"
FT                   /id="VAR_067239"
FT   VARIANT         141
FT                   /note="A -> T (in ALD; dbSNP:rs193922097)"
FT                   /evidence="ECO:0000269|PubMed:7581394"
FT                   /id="VAR_000033"
FT   VARIANT         143
FT                   /note="P -> S (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10369742,
FT                   ECO:0000269|PubMed:10480364"
FT                   /id="VAR_009354"
FT   VARIANT         148
FT                   /note="N -> S (in ALD; ADO-type; dbSNP:rs128624216)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:10480364, ECO:0000269|PubMed:20661612,
FT                   ECO:0000269|PubMed:7849723, ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000034"
FT   VARIANT         149
FT                   /note="S -> N (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:7825602"
FT                   /id="VAR_000035"
FT   VARIANT         152
FT                   /note="R -> L (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009355"
FT   VARIANT         152
FT                   /note="R -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:7825602"
FT                   /id="VAR_000037"
FT   VARIANT         152
FT                   /note="R -> S (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10737980"
FT                   /id="VAR_009356"
FT   VARIANT         161
FT                   /note="S -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009357"
FT   VARIANT         163
FT                   /note="R -> H (in ALD; dbSNP:rs1057517954)"
FT                   /evidence="ECO:0000269|PubMed:7825602"
FT                   /id="VAR_000038"
FT   VARIANT         163
FT                   /note="R -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009358"
FT   VARIANT         174
FT                   /note="Y -> C (in ALD; dbSNP:rs1557052390)"
FT                   /evidence="ECO:0000269|PubMed:10737980"
FT                   /id="VAR_009359"
FT   VARIANT         174
FT                   /note="Y -> D (in ALD; ALD-type; dbSNP:rs128624217)"
FT                   /evidence="ECO:0000269|PubMed:7849723,
FT                   ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000039"
FT   VARIANT         174
FT                   /note="Y -> S (in ALD; CALD-type and AMN-type;
FT                   dbSNP:rs1557052390)"
FT                   /evidence="ECO:0000269|PubMed:28456143,
FT                   ECO:0000269|PubMed:7860075"
FT                   /id="VAR_000040"
FT   VARIANT         178
FT                   /note="Q -> E (in ALD; AMN-type)"
FT                   /evidence="ECO:0000269|PubMed:7717396"
FT                   /id="VAR_000041"
FT   VARIANT         182
FT                   /note="R -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:7581394"
FT                   /id="VAR_000043"
FT   VARIANT         189
FT                   /note="R -> W (in ALD; dbSNP:rs1131691916)"
FT                   /evidence="ECO:0000269|PubMed:10737980"
FT                   /id="VAR_009360"
FT   VARIANT         190
FT                   /note="L -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10480364"
FT                   /id="VAR_009361"
FT   VARIANT         194
FT                   /note="D -> H (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:7825602"
FT                   /id="VAR_000044"
FT   VARIANT         198
FT                   /note="T -> K (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009362"
FT   VARIANT         198
FT                   /note="T -> R (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:21700483"
FT                   /id="VAR_067240"
FT   VARIANT         200
FT                   /note="D -> N (in ALD; dbSNP:rs2091708688)"
FT                   /evidence="ECO:0000269|PubMed:10190819"
FT                   /id="VAR_009363"
FT   VARIANT         200
FT                   /note="D -> V (in ALD; CALD-type)"
FT                   /evidence="ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000045"
FT   VARIANT         207
FT                   /note="S -> SAAS (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013343"
FT   VARIANT         211
FT                   /note="L -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000046"
FT   VARIANT         213
FT                   /note="S -> C (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:9553942"
FT                   /id="VAR_009364"
FT   VARIANT         214
FT                   /note="N -> D (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:20661612"
FT                   /id="VAR_009365"
FT   VARIANT         217
FT                   /note="K -> E (in ALD; not able to restore defective
FT                   beta-oxidation in fibroblast from patients with ALD)"
FT                   /evidence="ECO:0000269|PubMed:11438993"
FT                   /id="VAR_013344"
FT   VARIANT         218
FT                   /note="P -> T (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10737980"
FT                   /id="VAR_009366"
FT   VARIANT         220
FT                   /note="L -> P (in ALD; dbSNP:rs2091709142)"
FT                   /evidence="ECO:0000269|PubMed:7825602"
FT                   /id="VAR_000047"
FT   VARIANT         221
FT                   /note="D -> G (in ALD; CALD and AMN-types)"
FT                   /evidence="ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000048"
FT   VARIANT         224
FT                   /note="V -> E (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013345"
FT   VARIANT         229
FT                   /note="L -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10737980"
FT                   /id="VAR_009367"
FT   VARIANT         254
FT                   /note="T -> M (in ALD; AMN-type; dbSNP:rs1131691743)"
FT                   /evidence="ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000049"
FT   VARIANT         254
FT                   /note="T -> P (in ALD; AMN-type)"
FT                   /evidence="ECO:0000269|PubMed:20661612"
FT                   /id="VAR_000050"
FT   VARIANT         263
FT                   /note="P -> L (in ALD; CALD, AMN and AD-types)"
FT                   /evidence="ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000051"
FT   VARIANT         266
FT                   /note="G -> E (in ALD; dbSNP:rs2091711094)"
FT                   /evidence="ECO:0000269|PubMed:21700483"
FT                   /id="VAR_067241"
FT   VARIANT         266
FT                   /note="G -> R (in ALD; dbSNP:rs128624218)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:20661612, ECO:0000269|PubMed:21700483,
FT                   ECO:0000269|PubMed:21966424, ECO:0000269|PubMed:7825602,
FT                   ECO:0000269|PubMed:7849723"
FT                   /id="VAR_000052"
FT   VARIANT         271
FT                   /note="E -> K (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:20661612"
FT                   /id="VAR_009368"
FT   VARIANT         274
FT                   /note="R -> W (in ALD; uncertain significance;
FT                   dbSNP:rs782760033)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013346"
FT   VARIANT         276
FT                   /note="K -> E (in ALD; CALD-type)"
FT                   /evidence="ECO:0000269|PubMed:7668254"
FT                   /id="VAR_000053"
FT   VARIANT         277
FT                   /note="G -> GN (in ALD; ADO-type)"
FT                   /evidence="ECO:0000269|PubMed:10227685"
FT                   /id="VAR_000055"
FT   VARIANT         277
FT                   /note="G -> R (in ALD; AMN-type; dbSNP:rs1603232195)"
FT                   /evidence="ECO:0000269|PubMed:20661612,
FT                   ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000054"
FT   VARIANT         277
FT                   /note="G -> W (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:7581394"
FT                   /id="VAR_000056"
FT   VARIANT         280
FT                   /note="R -> C (in ALD; dbSNP:rs193922098)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013347"
FT   VARIANT         285
FT                   /note="R -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009369"
FT   VARIANT         291
FT                   /note="E -> D (in ALD; ACALD and CALD-types)"
FT                   /evidence="ECO:0000269|PubMed:7668254"
FT                   /id="VAR_000057"
FT   VARIANT         291
FT                   /note="E -> K (in ALD; dbSNP:rs128624213)"
FT                   /evidence="ECO:0000269|PubMed:7904210"
FT                   /id="VAR_000058"
FT   VARIANT         291
FT                   /note="Missing (in ALD; ALD-type)"
FT                   /evidence="ECO:0000269|PubMed:7668254"
FT                   /id="VAR_000059"
FT   VARIANT         294
FT                   /note="A -> T (in ALD; AMN-type; dbSNP:rs1131691954)"
FT                   /evidence="ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000060"
FT   VARIANT         296
FT                   /note="Y -> C (in ALD; dbSNP:rs797044610)"
FT                   /evidence="ECO:0000269|PubMed:10190819"
FT                   /id="VAR_009370"
FT   VARIANT         298
FT                   /note="G -> D (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10480364,
FT                   ECO:0000269|PubMed:10737980"
FT                   /id="VAR_009371"
FT   VARIANT         300
FT                   /note="E -> EVGQ (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11810273"
FT                   /id="VAR_013348"
FT   VARIANT         302
FT                   /note="E -> K (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:21966424"
FT                   /id="VAR_009372"
FT   VARIANT         316
FT                   /note="Q -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:26686776"
FT                   /id="VAR_075285"
FT   VARIANT         322
FT                   /note="L -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:9584268"
FT                   /id="VAR_009373"
FT   VARIANT         336
FT                   /note="K -> M (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009374"
FT   VARIANT         339
FT                   /note="W -> R (in ALD; dbSNP:rs1603233120)"
FT                   /evidence="ECO:0000269|PubMed:10480364"
FT                   /id="VAR_013349"
FT   VARIANT         342
FT                   /note="S -> P (in ALD; AMN-type)"
FT                   /evidence="ECO:0000269|PubMed:7668254"
FT                   /id="VAR_000061"
FT   VARIANT         343
FT                   /note="G -> D (in ALD; dbSNP:rs2091726809)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013350"
FT   VARIANT         389
FT                   /note="R -> G (in ALD; AMN-type; dbSNP:rs128624215)"
FT                   /evidence="ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000062"
FT   VARIANT         389
FT                   /note="R -> H (in ALD; does not affect protein stability,
FT                   homo- and heterodimerization with ABCD2 and ABCD3;
FT                   dbSNP:rs886044777)"
FT                   /evidence="ECO:0000269|PubMed:10551832,
FT                   ECO:0000269|PubMed:7581394, ECO:0000269|PubMed:7668254,
FT                   ECO:0000269|PubMed:7825602"
FT                   /id="VAR_000063"
FT   VARIANT         401
FT                   /note="R -> Q (in ALD; ALD and AMN-types; does not affect
FT                   protein stability, homo- and heterodimerization with ABCD2
FT                   and ABCD3; dbSNP:rs128624219)"
FT                   /evidence="ECO:0000269|PubMed:10551832,
FT                   ECO:0000269|PubMed:10737980, ECO:0000269|PubMed:10980539,
FT                   ECO:0000269|PubMed:21889498, ECO:0000269|PubMed:21966424,
FT                   ECO:0000269|PubMed:7668254, ECO:0000269|PubMed:7849723,
FT                   ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000064"
FT   VARIANT         401
FT                   /note="R -> W (in ALD; dbSNP:rs727503786)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:10737980, ECO:0000269|PubMed:20661612,
FT                   ECO:0000269|PubMed:21700483"
FT                   /id="VAR_009375"
FT   VARIANT         418
FT                   /note="R -> W (in ALD; AMN-type; dbSNP:rs128624220)"
FT                   /evidence="ECO:0000269|PubMed:10737980,
FT                   ECO:0000269|PubMed:10980539, ECO:0000269|PubMed:7849723,
FT                   ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000065"
FT   VARIANT         427
FT                   /note="Missing (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013351"
FT   VARIANT         484
FT                   /note="P -> R (in ALD; CALD, AMN and ADO-types;
FT                   significantly decreases homodimerization and abolishes
FT                   heterodimerization with ABCD2 and ABCD3;
FT                   dbSNP:rs128624214)"
FT                   /evidence="ECO:0000269|PubMed:10551832"
FT                   /id="VAR_000066"
FT   VARIANT         507
FT                   /note="G -> V (in ALD; CALD-types)"
FT                   /evidence="ECO:0000269|PubMed:10190819"
FT                   /id="VAR_000067"
FT   VARIANT         512
FT                   /note="G -> S (in ALD; CALD and AS-types; reduced ATPase
FT                   activity; dbSNP:rs1569541088)"
FT                   /evidence="ECO:0000269|PubMed:11248239,
FT                   ECO:0000269|PubMed:7561948, ECO:0000269|PubMed:7581394,
FT                   ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000068"
FT   VARIANT         515
FT                   /note="S -> F (in ALD; dbSNP:rs128624223)"
FT                   /evidence="ECO:0000269|PubMed:7849723"
FT                   /id="VAR_000069"
FT   VARIANT         516
FT                   /note="L -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:21889498"
FT                   /id="VAR_067328"
FT   VARIANT         518
FT                   /note="R -> Q (in ALD; CALD-type; dbSNP:rs398123102)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:11438993, ECO:0000269|PubMed:20661612,
FT                   ECO:0000269|PubMed:21700483"
FT                   /id="VAR_000070"
FT   VARIANT         518
FT                   /note="R -> W (in ALD; CALD-type; dbSNP:rs128624224)"
FT                   /evidence="ECO:0000269|PubMed:20661612,
FT                   ECO:0000269|PubMed:8040304, ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000071"
FT   VARIANT         522
FT                   /note="G -> W (in ALD; AD-type)"
FT                   /evidence="ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000072"
FT   VARIANT         523
FT                   /note="L -> F (in ALD; dbSNP:rs1159943880)"
FT                   /evidence="ECO:0000269|PubMed:21700483"
FT                   /id="VAR_067242"
FT   VARIANT         528
FT                   /note="Missing (in ALD; CALD-type)"
FT                   /evidence="ECO:0000269|PubMed:7717396"
FT                   /id="VAR_000073"
FT   VARIANT         529
FT                   /note="G -> S (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10480364"
FT                   /id="VAR_009376"
FT   VARIANT         534
FT                   /note="P -> L (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:7561948"
FT                   /id="VAR_000074"
FT   VARIANT         540
FT                   /note="F -> C (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:21700483"
FT                   /id="VAR_067243"
FT   VARIANT         540
FT                   /note="F -> S (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:20661612"
FT                   /id="VAR_009377"
FT   VARIANT         543
FT                   /note="P -> L (in ALD; dbSNP:rs1557054776)"
FT                   /evidence="ECO:0000269|PubMed:10737980,
FT                   ECO:0000269|PubMed:10980539"
FT                   /id="VAR_009378"
FT   VARIANT         544
FT                   /note="Q -> R (in ALD; dbSNP:rs2091763089)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:20661612"
FT                   /id="VAR_009379"
FT   VARIANT         552
FT                   /note="S -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10227685"
FT                   /id="VAR_009380"
FT   VARIANT         554
FT                   /note="R -> H (in ALD; dbSNP:rs201568579)"
FT                   /evidence="ECO:0000269|PubMed:10737980"
FT                   /id="VAR_009381"
FT   VARIANT         556
FT                   /note="Q -> R (in ALD; ACALD type)"
FT                   /evidence="ECO:0000269|PubMed:10980539"
FT                   /id="VAR_013352"
FT   VARIANT         560
FT                   /note="P -> L (in ALD; CALD-type; dbSNP:rs398123105)"
FT                   /evidence="ECO:0000269|PubMed:20661612,
FT                   ECO:0000269|PubMed:21700483, ECO:0000269|PubMed:21889498,
FT                   ECO:0000269|PubMed:7717396"
FT                   /id="VAR_000075"
FT   VARIANT         560
FT                   /note="P -> R (in ALD; AMN and ALMD-types)"
FT                   /evidence="ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000076"
FT   VARIANT         560
FT                   /note="P -> S (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013353"
FT   VARIANT         566
FT                   /note="M -> K (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:7581394"
FT                   /id="VAR_000077"
FT   VARIANT         591
FT                   /note="R -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013354"
FT   VARIANT         591
FT                   /note="R -> Q (in ALD; AMN-type; significantly decreases
FT                   homodimerization and abolishes heterodimerization with
FT                   ABCD2 and ABCD3; dbSNP:rs1557054873)"
FT                   /evidence="ECO:0000269|PubMed:10551832,
FT                   ECO:0000269|PubMed:7668254"
FT                   /id="VAR_000078"
FT   VARIANT         591
FT                   /note="R -> W (in ALD; dbSNP:rs398123106)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:21966424"
FT                   /id="VAR_009382"
FT   VARIANT         606
FT                   /note="S -> L (in ALD; decreased ATP-binding affinity;
FT                   dbSNP:rs128624225)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:11248239, ECO:0000269|PubMed:7581394,
FT                   ECO:0000269|PubMed:7668254, ECO:0000269|PubMed:8040304"
FT                   /id="VAR_000079"
FT   VARIANT         606
FT                   /note="S -> P (in ALD; uncertain significance; CALD, AMN
FT                   and ALMD-types; dbSNP:rs201774661)"
FT                   /evidence="ECO:0000269|PubMed:21700483,
FT                   ECO:0000269|PubMed:21889498, ECO:0000269|PubMed:21966424,
FT                   ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000080"
FT   VARIANT         608
FT                   /note="G -> D (in ALD; uncertain significance; CALD-type;
FT                   dbSNP:rs78993751)"
FT                   /evidence="ECO:0000269|PubMed:11438993"
FT                   /id="VAR_013355"
FT   VARIANT         609
FT                   /note="E -> G (in ALD; dbSNP:rs1557055260)"
FT                   /evidence="ECO:0000269|PubMed:7825602"
FT                   /id="VAR_000081"
FT   VARIANT         609
FT                   /note="E -> K (in ALD; AMN-type; dbSNP:rs150346282)"
FT                   /evidence="ECO:0000269|PubMed:20661612,
FT                   ECO:0000269|PubMed:21966424, ECO:0000269|PubMed:7825602,
FT                   ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000082"
FT   VARIANT         616
FT                   /note="A -> V (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10737980"
FT                   /id="VAR_009383"
FT   VARIANT         617
FT                   /note="R -> C (in ALD; ALD-type and asymptomatic;
FT                   dbSNP:rs4010613)"
FT                   /evidence="ECO:0000269|PubMed:7825602,
FT                   ECO:0000269|PubMed:8040304, ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000083"
FT   VARIANT         617
FT                   /note="R -> G (in ALD; ADO and AMN-types with cerebral
FT                   involvement)"
FT                   /evidence="ECO:0000269|PubMed:8566952"
FT                   /id="VAR_000084"
FT   VARIANT         617
FT                   /note="R -> H (in ALD; dbSNP:rs11146842)"
FT                   /evidence="ECO:0000269|PubMed:21700483,
FT                   ECO:0000269|PubMed:7581394, ECO:0000269|PubMed:7668254,
FT                   ECO:0000269|PubMed:8040304"
FT                   /id="VAR_000085"
FT   VARIANT         626
FT                   /note="A -> D (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013356"
FT   VARIANT         626
FT                   /note="A -> T (in ALD; CALD and AMN-types;
FT                   dbSNP:rs1557055316)"
FT                   /evidence="ECO:0000269|PubMed:21700483,
FT                   ECO:0000269|PubMed:7668254"
FT                   /id="VAR_000086"
FT   VARIANT         629
FT                   /note="D -> H (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:7668254"
FT                   /id="VAR_000087"
FT   VARIANT         630
FT                   /note="E -> G (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009384"
FT   VARIANT         631
FT                   /note="C -> Y (in ALD; dbSNP:rs2091773525)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009385"
FT   VARIANT         632
FT                   /note="T -> I (in ALD; dbSNP:rs1064793877)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013357"
FT   VARIANT         632
FT                   /note="T -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:21700483"
FT                   /id="VAR_067244"
FT   VARIANT         633
FT                   /note="S -> I (in ALD; asymptomatic)"
FT                   /evidence="ECO:0000269|PubMed:11438993"
FT                   /id="VAR_013358"
FT   VARIANT         633
FT                   /note="S -> R (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10737980,
FT                   ECO:0000269|PubMed:21700483"
FT                   /id="VAR_009386"
FT   VARIANT         635
FT                   /note="V -> M (in ALD; dbSNP:rs201427153)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_013359"
FT   VARIANT         636
FT                   /note="S -> I (in ALD; dbSNP:rs2091773697)"
FT                   /evidence="ECO:0000269|PubMed:9553942"
FT                   /id="VAR_009387"
FT   VARIANT         638
FT                   /note="D -> Y (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10480364"
FT                   /id="VAR_009388"
FT   VARIANT         640
FT                   /note="E -> K (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:21700483"
FT                   /id="VAR_067245"
FT   VARIANT         646
FT                   /note="A -> P (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:10737980"
FT                   /id="VAR_009389"
FT   VARIANT         654
FT                   /note="L -> P (in ALD; dbSNP:rs2091774046)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009390"
FT   VARIANT         657
FT                   /note="Missing (in ALD; CALD-type)"
FT                   /evidence="ECO:0000269|PubMed:10227685"
FT                   /id="VAR_000088"
FT   VARIANT         660
FT                   /note="R -> P (in ALD; CALD-type)"
FT                   /evidence="ECO:0000269|PubMed:11438993"
FT                   /id="VAR_013360"
FT   VARIANT         660
FT                   /note="R -> Q (in ALD; dbSNP:rs1557055340)"
FT                   /evidence="ECO:0000269|PubMed:21889498,
FT                   ECO:0000269|PubMed:21966424"
FT                   /id="VAR_067329"
FT   VARIANT         660
FT                   /note="R -> W (in ALD; CALD, ALMD and AS-types;
FT                   dbSNP:rs1569541203)"
FT                   /evidence="ECO:0000269|PubMed:10190819,
FT                   ECO:0000269|PubMed:20661612, ECO:0000269|PubMed:7561948,
FT                   ECO:0000269|PubMed:7581394, ECO:0000269|PubMed:7668254,
FT                   ECO:0000269|PubMed:7825602, ECO:0000269|PubMed:8651290"
FT                   /id="VAR_000089"
FT   VARIANT         667
FT                   /note="H -> D (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009391"
FT   VARIANT         668
FT                   /note="T -> I (in ALD; dbSNP:rs1557055398)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009392"
FT   VARIANT         677
FT                   /note="G -> D (in ALD)"
FT                   /evidence="ECO:0000269|PubMed:21700483"
FT                   /id="VAR_067246"
FT   VARIANT         679
FT                   /note="W -> R (in ALD; AMN-type; dbSNP:rs1557055405)"
FT                   /evidence="ECO:0000269|PubMed:9452087"
FT                   /id="VAR_000090"
FT   VARIANT         693
FT                   /note="T -> M (in ALD; dbSNP:rs782311214)"
FT                   /evidence="ECO:0000269|PubMed:11748843"
FT                   /id="VAR_009393"
FT   MUTAGEN         67
FT                   /note="M->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         68
FT                   /note="N->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         69
FT                   /note="R->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         70
FT                   /note="V->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         71
FT                   /note="F->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         72
FT                   /note="L->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         73
FT                   /note="Q->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         74
FT                   /note="R->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         75
FT                   /note="L->P: Impairs PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         76
FT                   /note="L->P: Impairs PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         77
FT                   /note="W->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         78
FT                   /note="L->P: Impairs PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         79
FT                   /note="L->P: Impairs PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         80
FT                   /note="R->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         81
FT                   /note="L->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         82
FT                   /note="L->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         83
FT                   /note="F->P: Does not affect PEX19 interaction."
FT                   /evidence="ECO:0000269|PubMed:15781447"
FT   MUTAGEN         513
FT                   /note="K->A: Does not affect ACOT activity. Transport
FT                   activity of VLCFA is strongly reduced."
FT                   /evidence="ECO:0000269|PubMed:33500543"
FT   CONFLICT        123
FT                   /note="V -> A (in Ref. 1; CAA79922/CAA83230)"
FT                   /evidence="ECO:0000305"
FT   STRAND          66..68
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           69..82
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          85..88
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           89..111
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          113..115
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           116..119
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          122..125
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           127..137
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   TURN            138..141
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           142..174
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          176..178
FT                   /evidence="ECO:0007829|PDB:7SHM"
FT   HELIX           179..185
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          189..191
FT                   /evidence="ECO:0007829|PDB:7SHN"
FT   HELIX           193..214
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           217..236
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          237..239
FT                   /evidence="ECO:0007829|PDB:7RR9"
FT   HELIX           242..253
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           256..259
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   TURN            262..264
FT                   /evidence="ECO:0007829|PDB:7SHN"
FT   TURN            265..267
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           268..288
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           290..296
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           299..331
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   TURN            332..339
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           340..343
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           349..351
FT                   /evidence="ECO:0007829|PDB:7XEC"
FT   HELIX           352..355
FT                   /evidence="ECO:0007829|PDB:7XEC"
FT   HELIX           363..370
FT                   /evidence="ECO:0007829|PDB:7XEC"
FT   HELIX           374..378
FT                   /evidence="ECO:0007829|PDB:7SHN"
FT   STRAND          379..381
FT                   /evidence="ECO:0007829|PDB:7XEC"
FT   HELIX           385..388
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   TURN            389..391
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           392..403
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           406..429
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   TURN            430..432
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          466..469
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          475..478
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   TURN            484..486
FT                   /evidence="ECO:0007829|PDB:7SHN"
FT   STRAND          488..491
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          494..496
FT                   /evidence="ECO:0007829|PDB:7RR9"
FT   STRAND          503..506
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          511..513
FT                   /evidence="ECO:0007829|PDB:7SHM"
FT   HELIX           515..520
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          522..524
FT                   /evidence="ECO:0007829|PDB:7SHM"
FT   STRAND          528..533
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           536..538
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          539..542
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          550..552
FT                   /evidence="ECO:0007829|PDB:7RR9"
FT   HELIX           553..557
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   TURN            558..560
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           563..568
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           575..582
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           586..589
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   TURN            591..593
FT                   /evidence="ECO:0007829|PDB:7SHN"
FT   HELIX           594..596
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           601..604
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   TURN            607..610
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           611..621
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          624..630
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   TURN            631..634
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           637..649
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          653..657
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           664..666
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          668..673
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          675..677
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   STRAND          679..683
FT                   /evidence="ECO:0007829|PDB:7VX8"
FT   HELIX           686..688
FT                   /evidence="ECO:0007829|PDB:7VR1"
FT   HELIX           690..694
FT                   /evidence="ECO:0007829|PDB:7VR1"
SQ   SEQUENCE   745 AA;  82937 MW;  82F90905F71FFDC8 CRC64;
     MPVLSRPRPW RGNTLKRTAV LLALAAYGAH KVYPLVRQCL APARGLQAPA GEPTQEASGV
     AAAKAGMNRV FLQRLLWLLR LLFPRVLCRE TGLLALHSAA LVSRTFLSVY VARLDGRLAR
     CIVRKDPRAF GWQLLQWLLI ALPATFVNSA IRYLEGQLAL SFRSRLVAHA YRLYFSQQTY
     YRVSNMDGRL RNPDQSLTED VVAFAASVAH LYSNLTKPLL DVAVTSYTLL RAARSRGAGT
     AWPSAIAGLV VFLTANVLRA FSPKFGELVA EEARRKGELR YMHSRVVANS EEIAFYGGHE
     VELALLQRSY QDLASQINLI LLERLWYVML EQFLMKYVWS ASGLLMVAVP IITATGYSES
     DAEAVKKAAL EKKEEELVSE RTEAFTIARN LLTAAADAIE RIMSSYKEVT ELAGYTARVH
     EMFQVFEDVQ RCHFKRPREL EDAQAGSGTI GRSGVRVEGP LKIRGQVVDV EQGIICENIP
     IVTPSGEVVV ASLNIRVEEG MHLLITGPNG CGKSSLFRIL GGLWPTYGGV LYKPPPQRMF
     YIPQRPYMSV GSLRDQVIYP DSVEDMQRKG YSEQDLEAIL DVVHLHHILQ REGGWEAMCD
     WKDVLSGGEK QRIGMARMFY HRPKYALLDE CTSAVSIDVE GKIFQAAKDA GIALLSITHR
     PSLWKYHTHL LQFDGEGGWK FEKLDSAARL SLTEEKQRLE QQLAGIPKMQ RRLQELCQIL
     GEAVAPAHVP APSPQGPGGL QGAST
//
